Company intelligence / Profile preview

Avella Specialty Pharmacy

Ownership: Private
Development stage: Other

Overview

Avella was a leading independent specialty pharmacy serving all 50 U.S. states. It provided access to complex therapies for serious conditions and offered patient support programs and technology solutions to improve medication adherence. In 2018 it was acquired by OptumRx.

Therapeutic areas: NeurologyInfectious DiseasesDermatologyOphthalmologyMen's HealthGastroenterologyOncologyRheumatologyWomen's Health
Modalities: Small moleculeBiologic
Industry: Non-Academic Healthcare

Partnerships

Sentry Data Systems (340B program partnership)Arizona Department of Health Services ADAP contract

Beyond the preview

Go deeper on Avella Specialty Pharmacy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avella Specialty Pharmacy.

Explore the full profile